PubChem CID 5351387 Formula C18H21O8P | ChemSpider 4508406 3D model (Jmol) Interactive image | |
 | ||
Synonyms CA4P; CA4PD; fosbretabulin; fosbretabulin disodium Molar mass 396.32 g/mol (exact mass : 396.097404) | ||
Combretastatin A-4 phosphate (phosbretabulin, and its salt phosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.
Combretastatin A-4 phosphate (CA4P) is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.
CA4P is also known as Fosbretabulin Tromethamine.
In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer. There is currently no fully FDA approved treatment for this form of cancer.
By 2017 it had completed multiple clinical trials (eg. for solid tumours, non-small cell lung cancer) with more in progress.